Welcome to our dedicated page for Innate Pharma S.A. news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has released its total number of shares outstanding and voting rights as of July 10, 2024. The company's share structure includes 80,969,357 ordinary shares, 6,494 Preferred Shares 2016, and 7,581 Preferred Shares 2017. The total number of theoretical voting rights stands at 81,724,597, while the total number of exercisable voting rights is 81,706,022. This disclosure is in compliance with French regulatory requirements and aims to keep the market adequately informed about the company's share structure and voting rights distribution.
Innate Pharma SA reported its total number of shares and voting rights as of June 10, 2024.
The company has 80,967,407 ordinary shares, 6,509 Preferred Shares 2016, and 7,581 Preferred Shares 2017.
The total number of theoretical voting rights stands at 81,724,597, while the number of exercisable voting rights is 81,706,022.
This information is disclosed to comply with regulations by the AMF, ensuring market transparency.
Innate Pharma's Phase 1/2 trial of SAR443579 (SAR’579), developed with Sanofi, continues to show promising results for treating relapsed/refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), and high-risk myelodysplasia (HR-MDS). The clinical trial results, presented at the European Hematology Association 2024 Congress, highlight 5 complete remissions at a 1 mg/kg dose, with 3 patients achieving durable CR over 10 months. SAR’579 has an FDA Fast Track Designation for acute myeloid leukemia and has shown a favorable safety profile at doses up to 6 mg/kg weekly. The study has now progressed to Phase 2, focusing on further demonstrating the efficacy of this NK cell engager.
Innate Pharma has announced positive results from its Phase 2 TELLOMAK study, evaluating lacutamab in patients with mycosis fungoides (MF), a type of cutaneous T cell lymphoma. The study, presented at ASCO 2024, included 107 heavily pretreated patients. Lacutamab demonstrated significant anti-tumor activity, with an objective response rate (ORR) of 22.4% per Olsen 2022 criteria and 16.8% per Olsen 2011 criteria. The median progression-free survival was 10.2 months, and the treatment was well-tolerated. These results support further development of lacutamab for MF patients, regardless of KIR3DL2 expression levels.
Innate Pharma (IPHA) will participate in several upcoming investor conferences. The company will be represented by senior executives including CEO Hervé Brailly, EVP Sonia Quaratino, COO Yannis Morel, and President of US Operations Arvind Sood. The schedule includes:
Jefferies Global Healthcare Conference on June 5-6, 2024, in New York.
Goldman Sachs 45th Annual Global Healthcare Conference on June 10-13, 2024, in Miami.
H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on June 25, 2024.
Stifel 2nd European Healthcare Summit on June 25-27, 2024, in Lyon.
Innate Pharma announced that five abstracts featuring its drug candidates have been accepted for presentation at the ASCO 2024 Annual Meeting, scheduled for May 31-June 4, 2024, in Chicago. Highlights include:
- Topline results of the TELLOMAK Phase 2 trial for lacutamab in mycosis fungoides, confirming promising clinical activity.
- Two posters on IPH6501, the second-generation ANKET® for CD20-expressing B-cell Non-Hodgkin's Lymphoma, presenting safety, tolerability, and preliminary antineoplastic activity.
- AstraZeneca's updated results for monalizumab in the Phase 2 COAST trial for stage III unresectable NSCLC.
- A poster on the Phase 2 MOZART trial of monalizumab combined with durvalumab and chemotherapy for the first-line treatment of extensive-stage small cell lung cancer.
These presentations underscore Innate Pharma’s commitment to advancing cancer immunotherapy.
Innate Pharma announced the results of its 2024 Annual General Meeting (AGM) held on May 23, 2024, in Marseille. The meeting had a quorum of 44.92% with 84 votes cast out of 36,317,268 shares, translating to 36,798,714 voting rights. All resolutions were passed, including the re-election of two Supervisory Board members. Detailed results, resolutions, and the AGM recording are available on the company's website.
Innate Pharma, listed on Euronext Paris (IPH) and Nasdaq (IPHA), clarified that their molecule SAR443579/IPH6101 was incorrectly mentioned as having breakthrough designation in an abstract published for the European Hematology Association 2024 Congress. The correct status is that the molecule has received US FDA Fast Track Designation, as communicated in June 2023. This clarification aims to rectify the misinformation released on May 14, 2024, by Sanofi.
Innate Pharma announced that four of its drug candidate abstracts have been accepted for presentation at the EHA 2024 Congress in Madrid, from June 13-16, 2024. Two abstracts focus on SAR443579 (IPH6101), an anti-CD123 NK cell engager developed with Sanofi, being tested in a Phase 1/2 trial for blood cancers. The other two abstracts highlight IPH6501, aimed at treating relapsed or refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma, also in Phase 1/2 trials. Chief Medical Officer Dr. Sonia Quaratino underscored the potential benefits of these NK cell engagers for patients with high unmet medical needs.
Innate Pharma (NASDAQ: IPHA) released its Q1 2024 business update, highlighting key developments in its clinical pipeline and financial performance. The company presented preclinical data for IPH45, an anti-Nectin-4 ADC, at AACR 2024 and advanced IPH6501, its second-generation ANKET®, into clinical development for NHL. Partner Sanofi progressed SAR443579/IPH6101 to Phase 2 in blood cancers. For Q1 2024, Innate reported revenues of €6.6 million, down from €26 million in Q1 2023. The company's cash position stood at €113.9 million as of March 31, 2024, excluding a pending €4 million milestone payment from Sanofi. Innate anticipates a cash runway until the end of 2025. Multiple presentations at ASCO 2024, including results from the TELLOMAK Phase 2 trial for lacutamab, are scheduled. The FDA lifted a partial clinical hold on lacutamab's IND in January 2024. A conference call to discuss these results will be held today.
FAQ
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
